NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹944 Cr | ₹973 Cr | ₹683 Cr | ₹710 Cr | ₹526 Cr |
What is the latest Total Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹944 Cr |
| Mar2024 | ₹973 Cr |
| Mar2023 | ₹683 Cr |
| Mar2022 | ₹710 Cr |
| Mar2021 | ₹526 Cr |
How is Total Current Liabilities of NATCO PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹944 Cr | -3.01 | |
| Mar2024 | ₹973 Cr | 42.41 | |
| Mar2023 | ₹683 Cr | -3.84 | |
| Mar2022 | ₹710 Cr | 35.16 | |
| Mar2021 | ₹526 Cr | - | |
Compare Total Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹18,408.8 Cr | 5.6% | 4% | 22% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,603.0 Cr | -5.6% | -2.5% | -1.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,485.0 Cr | -2.6% | -8.7% | 1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹135,009.0 Cr | -7.2% | -8% | 27.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,628.0 Cr | -6.5% | -5.4% | 3.9% | Stock Analytics | |
| CIPLA | ₹96,400.8 Cr | -4.1% | -11.5% | -19% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 5.6% |
4% |
22% |
| SENSEX | -1% |
-10.9% |
-6% |
You may also like the below Video Courses